Tiziana Life Sciences (NASDAQ:TLSA) Stock Price Down 0.5% - Should You Sell?

Key Points

• Tiziana Life Sciences stock price decreased by 0.5%, trading between $1.97 and $2.06, with recent volume down 28% from its average.
• Several institutional investors significantly increased their positions, including Jane Street Group LLC which raised its stake by 968.2%.
• The company's lead product candidate is Foralumab (TZLS-401), targeting multiple immunological diseases such as Crohn's disease and multiple sclerosis.

Tiziana Life Sciences Ltd (NASDAQ:TLSA - )'s stock price traded down 0.5% during trading on Friday . The stock traded as low as $1.97 and last traded at $2.06. 306,953 shares changed hands during mid-day trading, a decline of 28% from the average session volume of 427,048 shares. The stock had previously closed at $2.07.

Tiziana Life Sciences Stock Down 0.5%

The company's fifty day simple moving average is $1.93 and its 200 day simple moving average is $1.55.

Institutional Trading of Tiziana Life Sciences

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Marshall Wace LLP purchased a new stake in shares of Tiziana Life Sciences during the 2nd quarter valued at $39,000. Jane Street Group LLC raised its position in shares of Tiziana Life Sciences by 968.2% during the 1st quarter. Jane Street Group LLC now owns 167,542 shares of the company's stock valued at $181,000 after buying an additional 151,858 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new stake in shares of Tiziana Life Sciences during the 1st quarter valued at $25,000. OMERS ADMINISTRATION Corp purchased a new stake in shares of Tiziana Life Sciences during the 1st quarter valued at $156,000. Finally, Dauntless Investment Group LLC purchased a new stake in shares of Tiziana Life Sciences during the 1st quarter valued at $1,879,000.

About Tiziana Life Sciences

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.